Serum autoantibody to sideroflexin 3 as a novel tumor marker for oral squamous cell carcinoma

Ryuichi Murase, Yasuhito Abe, Takashi Takeuchi, Motowo Nabeta, Yoshinori Imai, Yoshiaki Kamei, Lisa Kagawa-Miki, Norifumi Ueda, Tomoki Sumida, Hiroyuki Hamakawa, Katusmi Kito

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The purpose of this study is to establish a tumor marker that can be applied for the early detection and follow-up of oral cancer patients. Employing the proteomic approach using MALDI TOF-MS, 2-DE, patient's sera and culturing cell lines, the serum autoantibodies (autoAbs) were screened and the serum levels were estimated by ELISA. Targeting the tumor cell invasion into the surrounding stromal tissues, MRC-5 human fibroblasts were employed as the target cells and a mitochondrial membrane protein, sideroflexin 3 (SFXN3), was identified. The serum anti-SFXN3-autoAb levels elevated in patients with the oral squamous cell carcinoma significantly: with 77% sensitivity and 89% specificity against control samples. The serum anti-SFXN3-autoAb levels were mildly correlated with the primary tumor sizes, however, the levels were slightly highly elevated in T1 early cancer. An immunohistochemical analysis revealed that the SFXN3 protein is expressed in the stromal fibroblasts between the caner nests and also in the basal layer of the squamous epithelium. Changes in the serum anti-SFXN3-autoAb levels after therapy correlated with the clinical tumor burden. These findings demonstrated that the serum anti-SFXN3-autoAb is worthy of clinical evaluation as a potentially of the novel tumor maker for the early detection of oral squamous cell carcinoma.

Original languageEnglish
Pages (from-to)517-527
Number of pages11
JournalProteomics - Clinical Applications
Volume2
Issue number4
DOIs
Publication statusPublished - Apr 1 2008

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this